MoonLake Immunotherapeutics (NASDAQ:MLTX) Issues Quarterly Earnings Results, Meets Estimates

MoonLake Immunotherapeutics (NASDAQ:MLTX) announced its earnings results on Wednesday. The company reported ($0.97) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.97), Briefing.com reports. During the same period last year, the business earned ($0.72) EPS.

MoonLake Immunotherapeutics Price Performance

Shares of MoonLake Immunotherapeutics stock traded up $0.01 on Wednesday, hitting $18.21. 628,771 shares of the company were exchanged, compared to its average volume of 2,633,559. MoonLake Immunotherapeutics has a 1-year low of $5.95 and a 1-year high of $62.75. The company has a quick ratio of 8.50, a current ratio of 8.50 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $1.17 billion, a price-to-earnings ratio of -5.48 and a beta of 1.21. The company has a 50-day moving average price of $15.38 and a 200 day moving average price of $23.61.

Insiders Place Their Bets

In other MoonLake Immunotherapeutics news, CEO Da Silva Jorge Santos sold 130,000 shares of the company’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $15.08, for a total value of $1,960,400.00. Following the completion of the sale, the chief executive officer directly owned 2,948,577 shares in the company, valued at $44,464,541.16. This represents a 4.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Kristian Reich sold 130,000 shares of the firm’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $15.08, for a total value of $1,960,400.00. Following the completion of the sale, the insider directly owned 72,908 shares of the company’s stock, valued at $1,099,452.64. This trade represents a 64.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 402,908 shares of company stock worth $5,987,162 in the last three months. 12.05% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Kestra Advisory Services LLC acquired a new stake in shares of MoonLake Immunotherapeutics during the 4th quarter worth approximately $26,000. Russell Investments Group Ltd. grew its position in MoonLake Immunotherapeutics by 45.4% in the fourth quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company’s stock worth $45,000 after acquiring an additional 1,069 shares during the period. T. Rowe Price Investment Management Inc. acquired a new stake in MoonLake Immunotherapeutics during the fourth quarter worth $47,000. Bank of America Corp DE increased its stake in MoonLake Immunotherapeutics by 64.7% during the third quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock worth $32,000 after acquiring an additional 1,781 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in MoonLake Immunotherapeutics by 115.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock valued at $42,000 after purchasing an additional 3,166 shares during the period. 93.85% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

MLTX has been the topic of several analyst reports. Oppenheimer increased their price target on MoonLake Immunotherapeutics from $30.00 to $35.00 and gave the stock an “outperform” rating in a research report on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price objective on shares of MoonLake Immunotherapeutics in a report on Tuesday, February 3rd. The Goldman Sachs Group cut shares of MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating and boosted their target price for the stock from $8.00 to $10.00 in a research note on Wednesday, January 14th. Needham & Company LLC upped their price target on shares of MoonLake Immunotherapeutics from $20.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday. Finally, Royal Bank Of Canada lifted their price objective on MoonLake Immunotherapeutics from $10.00 to $12.00 and gave the stock a “sector perform” rating in a report on Friday, February 20th. Seven research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and five have issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $27.15.

Key MoonLake Immunotherapeutics News

Here are the key news stories impacting MoonLake Immunotherapeutics this week:

• Positive Sentiment: Positive sonelokimab data reported, highlighting improved clinical results that investors view as validation of the program and supportive of upcoming regulatory and commercial prospects. MoonLake turns the tables on sonelokimab with positive data
• Positive Sentiment: Analysts are increasing price targets: an article notes a PT raise to $22.30 (up ~11.25%), reflecting growing analyst confidence after the data. MoonLake Immunotherapeutics (MLTX) price target increased by 11.25% to 22.30
• Positive Sentiment: BTIG raised its price target to $30 and reiterated a Buy rating; Needham raised its target to $25 with a Buy — both moves signal institutional optimism and can drive demand. Benzinga coverage of analyst price-target changes
• Positive Sentiment: Lifesci Capital trimmed its Q4 2025 EPS loss estimate (from ($1.14) to ($0.90)), reducing near‑term earnings risk and improving street expectations. (No direct link provided)
• Neutral Sentiment: MoonLake published investor‑day materials (slides and transcript) that provide more detail on pipeline strategy, upcoming study readouts (e.g., phase 3 PsA in 2026) and commercial planning — useful for longer‑term thesis but not an immediate catalyst. Analyst/Investor Day – Slideshow Analyst/Investor Day – Transcript
• Negative Sentiment: One note downgraded MLTX from Strong Buy to Buy after a mixed phase‑3 outcome (VELA‑2 missed its primary endpoint in HS). While the FDA Type B meeting was constructive and a BLA pathway remains, the missed endpoint injects short‑term uncertainty and could weigh on expectations if additional confirmation is needed. MoonLake: Downgrade To Buy As Sonelokimab Still Has A BLA Shot On Goal

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.